Skip to content

An observational study to evaluate the safety and tolerability of velnez nasal pack after nasal surgery as compare to other marketed nasal packs

An observational, open label, single centre, post marketing surveillance study to evaluate safety and tolerability of VELNEZ with other marketed products as nasal pack used in nasal surgery

Status
Active, not recruiting
Phases
Phase 4
Study type
Observational
Source
CTRI
Registry ID
CTRI/2017/07/008958
Enrollment
30
Registered
2017-07-03
Start date
Unknown
Completion date
Unknown
Last updated
2026-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- 2. The subject has a planned nasal surgery (either for septoplasty with or without FESS or turbinoplasty) Health Condition 2: O- Medical and Surgical

Interventions

Intervention1: VELNEZ: VELNEZ is a Biodegradable composite that fragments within few days on application intended as nasal dressing. The pain associated with the tradition nasal pack removal is comple

Sponsors

Datt Mediproducts Pvt Ltd
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Age in between 18-60 years. 2. The subject has a planned nasal surgery (either for septoplasty with or without FESS or turbinoplasty). 3. Subjects who can provide informed consent form in writing and medically in a position to undergo consent and screening processes. 4. The subject is willing and able to comply with the requirements of the study protocol, including the predefined follow-up evaluations.

Exclusion criteria

Exclusion criteria: 1. Subjects with medical emergency, where treatment is more essential than the informed consent process and he or his representative deny to participate in study. 2. Subjects who cannot provide informed consent such as unconscious subjects. 3. Subjects unwilling or unable to comply with the postoperative visits necessary for data collection. 4. Subjects with severe rhinosinusitis involving all the paranasal sinuses associated with sinonasal polyposis, allergic fungal rhinosinusitis, gross septal deviation or spurs hitching on the ostiomeatal complex (OMC) region huge concha bullosa or allergic turbinate hypertrophy in contact with septum. 5. Subject has an active infection at the planned surgery site. 6. Subjects who have a history of previous septoplasty, allergy and/or asthma 7. Postoperative recurrent rhino sinusitis, patients with bleeding diathesis, 8. Subject on aspirin or anti-platelet drugs therapy. 9. hypertensive patients 10. Subjects who have a history of allergic (Hypersensitive) reactions with any of the ingredients of the device i.e Chitosan, Gelatin etc

Design outcomes

Primary

MeasureTime frame
Proportion of population, failure to cease haemorrhage after VELNEZ packing in nasal cavityTimepoint: 20 minutes

Secondary

MeasureTime frame
Difference in subject comfort level in compare of other VELNEZ/Biodegradable or Nonâ??Biodegradable nasal packs after nasal surgery in enrolled subjects.Timepoint: after surgery, at discharge, 2nd day, 4th day, 6th day, 8th day, 10th day, 2nd week, 3rd week and 4th week after Surgery

Countries

India

Contacts

Public ContactDr Rajan Datt

Datt Mediproducts Pvt. Limited

neeraj.kumar@dattmedi.com47191777

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Mar 14, 2026